Brandenburg, T. | Search bioRxiv

bioRxiv2025

ALK Inhibition Prolongs Survival in a Mouse Model of ALK-positive Anaplastic Thyroid Cancer

BackgroundAnaplastic thyroid cancer (ATC) is the most aggressive thyroid cancer with a median survival of about 6 months. So far, no therapies offering a survival benefit are established. Thus, new therapeutic approaches are urgently needed. In general, genetic alterations leading to ATC increase PI3K and MAPK/ERK signalling and include mutations in receptor tyrosine kinases and tumour suppressor genes. They often occur together with the loss of P53, the most prevalent mutation in human ATC. Among such mutations are mutations and rearrangements of the anaplastic lymphoma kinase (ALK) gene. MethodsTo study ATC and potential treatment options, we generated a mouse model with inducible thyrocyte-specific expression of constitutively active mutant ALKF1174L and homozygous deletion of Trp53 due to a Cre recombinase under control of the thyroglobulin promoter (Tg-CreERT2+/0;LSL-ALKF1174L/+;Trp53LoxP/LoxP mice, here referred to as Trp53KO/ALKF1174L mice). Moreover, we established several primary thyroid cancer cell lines harbouring ALKF1174L and Trp53KO and investigated the effects of ALK inhibition in vitro and in vivo. ResultsMedian survival of Trp53KO/ALKF1174L mice was severely reduced and the mice showed massively enlarged thyroids. Histopathology confirmed development of locally invasive and metastatic ATC. Treatment of primary Trp53KO/ALKF1174L ATC cells with the ALK inhibitor TAE-684 decreased AKT and ERK phosphorylation and induced a dose-dependent cytotoxicity. Trp53KO/ALKF1174L mice treated with TAE-684 showed significantly extended median survival compared to the solvent group (66 days vs. 18 days, p < 0.0001). ConclusionOur data demonstrate that the combination of ALKF1174L mutation with Trp53 loss leads to the development of ATC. This study provides first functional data supporting the use of ALK inhibitors in patients with ALK-driven ATC. Our novel ATC mouse model and the derived cell lines offer valuable tools to explore the molecular characteristics of ATC, especially signalling pathway activation and tumour microenvironment, and to test novel therapeutics for the treatment of advanced thyroid cancers.

cancer biology↗

bioRxiv2019

Viral infection overcomes ineffectiveness of anti-tumoral CD8+ T cell mediated cytotoxicity

With the integration of PD-1 and CTLA-4 targeting immune checkpoint blockade into cancer treatment regimes, the anti-tumoral cytotoxicity of tumor-specific CD8+ T cells is well established. However, while the unresponsiveness of CD8+ T cells against big tumors is mainly explained by T cell exhaustion, other factors contributing to CD8+ T cell failure remain not well studied. Here we used a mouse melanoma model to study the interaction of growing tumor cells, innate immunity and CD8+ T cell responses induced by viral replication. Mouse model of melanoma (B16F10-OVA) and infections with arenaviruses. Growing B16F10-OVA cells did not induce systemic ablation of tumor specific CD8+ T cells. However, despite the presence of tumor-infiltrating CD8+ T cells, the anti-tumoral immune response was very limited. T cell anergy against the tumor was accompanied with a strong down-regulation of MHC-I on advanced tumors. LCMV infection restored the MHC class I expression, enhanced T cell function and lead to tumor regression. This study shows that tumor progression does not necessary lead to systemic exhaustion of the anti-tumoral CD8+ T cell response. Lack of innate signals is an additional reason for limited CD8+ T cell mediated cytotoxicity against the tumor.

immunology↗